Antibiotic development consultant
Self-employed
Greg Moeck, PhD is a microbiologist with 25 years of experience in the biotech and pharmaceutical industries, specializing in antibacterial drug discovery and development. In his previous position at Venatorx Pharmaceuticals, Greg was engaged in the development of two investigational, clinical-stage antibacterial agents, cefepime-taniborbactam and ceftibuten-ledaborbactam. He also held senior positions at The Medicines Company and Targanta Therapeutics, where he contributed to the development and regulatory approval of oritavancin and meropenem-vaborbactam. He is an author of 80 peer-reviewed articles, four book chapters, and the Clinical and Laboratory Standard Institute (CLSI) M23 Guideline, and he holds several patents on novel methods of use of antibacterial agents. He obtained his PhD in Microbiology and Immunology from McGill University (Montreal, Canada) and was a Postdoctoral Research Fellow of the Ministry of Foreign Affairs, France, and of the Natural Sciences and Engineering Research Council, Canada for his research on nutrient uptake systems and interactions in the gram-negative bacterial cell envelope as targets for drug discovery. His professional service includes roles as Co-Chair of the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI; 2026), Editorial Board member of the American Society for Microbiology (ASM) journal Case Reports (2024-2026), Advisor to the CLSI Antimicrobial Susceptibility Testing (AST) Subcommittee (2016-2024), member of the Program Committee of the ASM/European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance (Porto, Portugal, 2024), and ad hoc reviewer for several scientific journals on antimicrobial agents research and development.
Disclosure(s): VenatoRx Pharmaceuticals Inc.: Prior employment
Wednesday, October 22, 2025
10:30 AM - 11:45 AM US ET